• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145-8.

作者信息

Wang Zhan, Zhao Yang, Zhang Yushi

机构信息

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Department of Urology, Peking Union Medical College Hospital, Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

出版信息

Eur Urol. 2022 Mar;81(3):e65. doi: 10.1016/j.eururo.2021.11.033. Epub 2021 Dec 23.

DOI:10.1016/j.eururo.2021.11.033
PMID:34953601
Abstract
摘要

相似文献

1
Re: Masayuki Hagiwara, Atsushi Fushimi, Kazuhiro Matsumoto, Mototsugu Oya. The Significance of PARP1 as a Biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma. Eur Urol. 2022;81:145-8.回复：萩原正之、伏见敦史、松本和弘、大谷元嗣。PARP1作为预测PBRM1突变型透明细胞肾细胞癌患者对PD-L1阻断反应的生物标志物的意义。《欧洲泌尿外科杂志》。2022年；81卷：145 - 148页。
Eur Urol. 2022 Mar;81(3):e65. doi: 10.1016/j.eururo.2021.11.033. Epub 2021 Dec 23.
2
The Significance of PARP1 as a biomarker for Predicting the Response to PD-L1 Blockade in Patients with PBRM1-mutated Clear Cell Renal Cell Carcinoma.PARP1 作为预测 PBRM1 突变型透明细胞肾细胞癌患者对 PD-L1 阻断反应的生物标志物的意义。
Eur Urol. 2022 Feb;81(2):145-148. doi: 10.1016/j.eururo.2021.09.024. Epub 2021 Oct 6.
3
Interrogating the Significance of PARP1 Expression and PBRM1 Mutation as Biomarkers for Predicting the Response to Atezolizumab plus Bevacizumab or to Sunitinib in Patients with Clear Cell Renal Cell Carcinoma.探讨PARP1表达和PBRM1突变作为生物标志物在预测透明细胞肾细胞癌患者对阿替利珠单抗联合贝伐单抗或舒尼替尼反应中的意义。
Eur Urol. 2022 Sep;82(3):334-335. doi: 10.1016/j.eururo.2022.05.013. Epub 2022 Jun 7.
4
Higher programmed cell death 1 ligand 1 (PD-L1) mRNA level in clear cell renal cell carcinomas is associated with a favorable outcome due to the active immune responses in tumor tissues.透明细胞肾细胞癌中较高的程序性细胞死亡1配体1（PD-L1）mRNA水平与肿瘤组织中的活跃免疫反应所导致的良好预后相关。
Oncotarget. 2017 Jan 10;8(2):3355-3363. doi: 10.18632/oncotarget.13765.
5
Combination Strategies for Immune Checkpoint Inhibitors in PBRM1-mutant Renal Cell Carcinoma: To PARP or Not To PARP?PBRM1 突变型肾细胞癌中免疫检查点抑制剂的联合策略：是否使用聚（ADP-核糖）聚合酶（PARP）抑制剂？
Eur Urol. 2022 Feb;81(2):149-150. doi: 10.1016/j.eururo.2021.10.028. Epub 2021 Nov 6.
6
PARP1 Suppresses the Transcription of PD-L1 by Poly(ADP-Ribosyl)ating STAT3.PARP1 通过多聚（ADP-核糖）化 STAT3 抑制 PD-L1 的转录。
Cancer Immunol Res. 2019 Jan;7(1):136-149. doi: 10.1158/2326-6066.CIR-18-0071. Epub 2018 Nov 6.
7
The Clinical Activity of PD-1/PD-L1 Inhibitors in Metastatic Non-Clear Cell Renal Cell Carcinoma.PD-1/PD-L1 抑制剂在转移性非透明细胞肾细胞癌中的临床活性。
Cancer Immunol Res. 2018 Jul;6(7):758-765. doi: 10.1158/2326-6066.CIR-17-0475. Epub 2018 May 10.
8
Inhibition of Tumor Growth and Sensitization to Sunitinib by RNA Interference Targeting Programmed Death-ligand 1 in Mouse Renal Cell Carcinoma RenCa Model.靶向程序性死亡配体 1 的 RNA 干扰抑制小鼠肾透明细胞癌 RenCa 模型中的肿瘤生长和对舒尼替尼的增敏作用。
Anticancer Res. 2019 Sep;39(9):4737-4742. doi: 10.21873/anticanres.13656.
9
Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.肾细胞癌伴肉瘤样去分化患者的程序性细胞死亡配体1及肿瘤浸润淋巴细胞状态
Cancer. 2017 Dec 15;123(24):4823-4831. doi: 10.1002/cncr.30937. Epub 2017 Aug 22.
10
Concordance of PD-1 and PD-L1 (B7-H1) in paired primary and metastatic clear cell renal cell carcinoma.配对的原发性和转移性透明细胞肾细胞癌中 PD-1 和 PD-L1（B7-H1）的一致性。
Cancer Med. 2020 Feb;9(3):1152-1160. doi: 10.1002/cam4.2769. Epub 2019 Dec 12.